Neglected cardiomyopathies in Africa by Mocumbi, Ana Olga H.
Neglected 
cardiomyopathies in Africa
Size of the problem
Cardiomyopathies constitute a huge burden to both communities 
and health systems in Africa. Together with rheumatic heart 
disease, tuberculous pericarditis, systemic hypertension and its 
complications, cardiomyopathies are the major causes of heart 
disease in black African populations, causing great morbidity and 
mortality in young and economically active people(6,7) and being 
responsible for more than 20% of all admissions for cardiovascular 
diseases in both children and adults.(8)
EMF, the most common cardiomyopathy in African children and 
adolescents, shows great geographic variation with areas of 
higher incidence being the tropical regions of East, Central and 
West of the continent,(9) where it accounts for up to 20% of 
cases of heart failure.(5,7,10) This regional variation in prevalence 
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CARDIOMYOPATHY
INTRODUCTION                                                               
Cardiomyopathies are forms of disease in which the heart 
muscle is structurally and functionally abnormal, in the absence 
of coronary artery disease, hypertension, valve disease and 
congenital heart disease suffi cient to explain the observed 
myocardial abnormality.(1) 
The diseases of the heart muscle constitute the greatest challenge 
of all the cardiovascular diseases in Africa(2) where, in addition 
to the cardiomyopathies usually seen in the developed world, 
there is a high prevalence of specifi c forms of myocardial disease 
which cause considerable morbid-mortality and affect large 
numbers of people, but have not been the subject of enough 
attention from the medical and research communities. They are 
part of the forgotten or neglected cardiovascular diseases. 
The most stricking example of neglected cardiomyopathy is 
Endomyocardial Fibrosis (EMF).(3) Despite being the most common 
form of restrictive cardiomyopathy worldwide, affecting an 
estimated 12 million people,(4) EMF has received little attention 
from the scientifi c community as shown by the declining number 
of publications on the subject in the last decades.(5)
Cardiomyopathies are forms of disease in which the heart 
muscle is structurally and functionally abnormal in the 
absence of coronary artery disease, hypertension, valve 
disease and congenital heart disease suffi cient to explain 
the observed myocardial abnormality. They constitute the 
greatest challenge of all the cardiovascular diseases in 
Africa, due to the diffi culties in diagnosing and managing 
them, related to the lack of access to specialised investi-
gations or effective interventions in most endemic areas. 
In this continent, in addition to the “usual” forms of 
cardiomyopathy, there is an increased incidence of specifi c 
forms of muscle heart disease like Endomyocardial Fibrosis 
and Peripartum Cardiomyopathy which, despite affecting 
thousands of people, have been largely neglected. Their 
etiology remains unknown, the mechanisms involved are 
not fully understood, and although some improvement in 
management has been witnessed in recent years much 
still need to be done to improve the outcome. 
The current knowledge on epidemiology, determinants, 
pathophysiology, diagnosis and management of Endomyo-
cardial Fibrosis and Peripartum Cardiomyopathy is reviewed 
in this article, which also presents the ongoing efforts for 
better understanding of their pathogenesis and the recent 




















occurs for reasons that are unclear(5) and within country regional 
variation has also been reported in Mozambique,(11) Uganda(12) and 
Nigeria.(13) 
Several studies in African countries revealed an incidence of 
Peripartum Cardiomyopathy (PPCM) varying from 1:500 to 
1:1000 deliveries.(14,15,16) This cardiomyopathy is known to have 
high incidence  and prevalence in the black race,(17,18,19) and studies 
in the USA have shown that African-American women had 
2.9-fold more cases of PPCM when compared with whites and 
7-fold more cases than Hispanic women.(20)
A new challenge for African countries is the HIV-related 
cardiomyopathy, which constitutes the most important cardio-
vascular manifestation of HIV infection with a prevalence varying 
from 10% to 30% in echocardiography or autopsy studies.(21,22,23) 
Its incidence increases with the progression of AIDS(22,23,24,25) and 
is likely to become even more prevalent as HIV-infected patients 
live longer. Rapid progression to death in less than 3 months has 
been reported in patients without antiretroviral therapy(26) either 
due to HIV-myocarditis or to opportunistic infections, autoimmune 
response to viral infection, and nutritional defi ciencies.(25,26,27,28) 
Dilated cardiomyopathy is now the leading cause of heart disease 
in acutely ill hospitalised patients with HIV in Africa,(29,30) parti-
cularly in those not receiving highly active antiretroviral therapy.(31) 
The advent of highly active antiretroviral therapy has had an 
impressive impact on mortality and disease progression in devel-
oped countries, but these effects are not yet seen in Africa due 
to lack of universal access to therapy. Similarly to other parts of 
the globe, some antiretroviral drugs have several side effects that 
can lead to cardiac dysfunction.(32) 
Although important due to the high number of people at risk in 
Africa, we will not discuss HIV-related cardiomyopathy in detail. 
Instead we will concentrate in reviewing the current knowledge on 
Endomyocardial Fibrosis and Peripartum Cardiomyopathy.
ENDOMYOCARDIAL FIBROSIS                                                      
Defi nition
Endomyocardial Fibrosis (EMF) is an extremely debilitating disease, 
classifi ed as a restrictive cardiomyopathy that is characterised by 
endocardial fi brous thickening, affecting predominantly the 
ventricular wall and the atrioventricular valves, which results in 
ventricular cavity reduction with abnormal diastolic fi lling, and 
severe tricuspid or mitral regurgitation. 
Etiology and determinants
The etiology of EMF remains unknown although several factors 
have been implicated in its origin. Ethnicity, poverty, malnutrition, 
dietary factors, infections (viral and parasitic), autoimmunity, allergy 
(eosinophilia), toxic agents (cerium, cassava, serotonin, plant toxins 
and vitamin D) and heredity have all been implicated.(5) 
The major determinants of EMF seem to be age, gender, ethnic 
group, social deprivation and eosinophilia.(12,33,34,35) This condition 
affects predominantly children with more than half the cases 
being diagnosed during the fi rst decade of life.(36) However, it can 
occur in infants(37) and a second peak incidence occurs in women 
of childbearing age.(4) 
Childhood EMF affects both sexes.(38) Female preponderance has 
been found in young adults from Uganda(39) while in Mozambique 
males are more affected.(33) 
Regarding ethnics, studies from Uganda reported preponderance 
of the condition in patients from Rwanda and Burundi that 
immigrate to the Southwest.(12,40) In Mozambique, an analysis 
of referrals to a tertiary unit showed a striking high attack rate in 
an ethnic group from a rural coastal area in the south of the 
country,(11) for reasons that could not be determined.
Familial cases of EMF have been described in both clinical(41,42) 
and epidemiological studies.(33) The most important conditioning 
factors seem to be environmental.(9,43) However, preliminary 
results of studies performed in Mozambican patients with EMF 
showed evidence of immunogenetic heterogeneity (Mocumbi, 
unpublished data). 
The role of infectious agents has been mainly supported by 
fi ndings of sporadic cases of EMF in foreign people from temper-
ate areas after short stays in endemic regions,(44,45) but it also 
appears plausible in view of climatic restrictions of the disease. 
Plasmodium species,(46) Schistosoma,(47) Microfi laria,(48) Helminths,(35) 
Coxsackie B virus,(49) Arboviruses and Toxoplasma gondii(49) have 
all been considered as possible causes or triggers for disease.
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Regarding the role of autoimmunity, studies in African populations 
showed evidence of higher prevalence of antiheart antibodies in 
EMF patients when compared to those with rheumatic heart 
disease, dilated cardiomyopathy and healthy controls.(46) However, 
it is not clear if these autoantibodies are the cause or the result 
of EMF, and pathological studies failed to show large numbers of 
immunologically competent cells at the endomyocardial junction, 
where EMF lesions are more prominent.(50) 
New evidence for autoimmunity was found in a large subset of 
EMF patients from Mozambique which serum was tested for 
the presence of anti-myocardial proteins. Strong   reactivity against 
myocardial proteins was found (Mocumbi unpublished data) 
corroborating fi ndings from India.(51) Although weaker, there was 
also increase in IgM reactivity when EMF patients were compared 
to healthy controls of the same population. 
None of these hypotheses is by itself suffi cient to explain the 
non-random geographical occurrence of EMF worldwide, nor can 
any of them explain the pathological fi ndings characteristic of this 
condition.
Pathophysiology 
Endomyocardial fi brosis appears to start as a febrile episode 
triggered by an unknown factor followed by ventricular thrombosis 
which can be associated with facial swelling, body itching, hyper-
eosinophilia and thromboembolism.(52,35) It is thought that mural 
and valvar thrombosis evolves to organisation of the thrombus 
and endocardial fi brosis, affecting mainly the ventricular apices and 
the recess behind the posterior leafl et of the mitral valve.(39) 
Mural endocardial fi brosis reduces ventricular cavity size and 
impedes adequate fi lling leading to restrictive physiology, while 
fi brosis of the endocardium affecting the papillary muscles, chordae 
and/or leafl ets causes valve distortion, resulting in severe atrio-
ventricular regurgitation. These two abnormalities are responsible 
for the typical aspect of small ventricles with severely dilated atria 
found in this entity.
The sustained low cardiac output results in fi nger and toe clubbing, 
growth retardation, testicular atrophy, failure to develop male 
secondary sexual characters and cachexia.(53,54,55,56) In right ventri-
cular EMF, the most common form of presentation either in 
isolation or as part of biventricular disease, chronic systemic 
venous hypertension leads to exophthalmos, elevated jugular 
pressure, gross hepatomegaly and congestive splenomegaly.(56) 
However, some distinctive features of EMF cannot be explained 
solely by low cardiac output and retrograde congestion. For 
instance, there is still some controversy regarding the patho-
physiology of the central cyanosis and the voluminous ascites 
that can lead to ventral or inguinal hernia in the absence of 
pedal oedema.(57) 
Diagnosis
The clinical picture of EMF depends on the ventricle affected, 
the duration of disease and the presence of active disease. By the 
time of clinical presentation patients with EMF are usually at an 
advanced stage(36) and most give poor clinical history. Interestingly, 
patients can be mildly symptomatic while having severe structural 
abnormalities detected on echocardiography.(58,59)
Patients with right-sided EMF often present with exophtalmus, 
jaundice, peripheral cyanosis, fi nger clubbing, atrial fi brillation, 
ascitis without pedal oedema, third sound and absence of cardiac 
murmurs due to free tricuspid regurgitation.(36)  In left-sided EMF 
there is usually a systolic murmur that is typically soft, short and 
confi ned to early systole, associated with a delayed opening snap, 
and a loud pulmonary component of the second sound, indicating 
increased pulmonary pressures.(60)
The biological profi le of EMF patients is unspecifi c. Hyper-
eosinophilia is a common fi nding(61) without any evidence of 
infection or parasitism.(62) The effusions, particularly the ascitic 
fl uid, are typically exudates having more leukocytes (predominantly 
lymphocytes) and higher protein content than expected in right 
heart failure.(63)
The electrocardiogram shows no constant pattern. There are 
usually low voltage QRS complexes, non-specifi c ST-T wave 
changes, conduction disturbances and atrial arrhythmias in ad-
vanced disease.(61) A tall and broad right atrial wave, “qr” pattern 
in the leads V3R or V1, and delayed right ventricular conduction 
are characteristic of right EMF.(56,57)
The chest x-ray in right ventricular EMF shows severe right atrial 
enlargement, a bulge over the left heart border due to dilatation 
of the infundibulum, and hypoperfused lungs, while in left-sided 
EMF there is prominent main pulmonary artery, exaggeration of 





















Echocardiography is the most valuable tool for diagnosis and 
usually reveals dense endocardial echos along different parts of 
the mural and valvar endocardium, valve dysfunction and a restric-
tive fi lling pattern. Characteristically there is obliteration of the 
trabecular portion of the right ventricle and, in advanced cases, 
shrinkage of the cavity with an apical notch, free tricuspid 
regurgitation, signs of spontaneous contrast, right atrial thrombi 
and pericardial effusion (Figure 1). Left disease usually shows patchy 
enhancement of the endocardial echo, thickening of the endo-
cardium of the LV apex that can be obliterated, plastered-down 
posterior mitral leafl et causing eccentric mitral regurgitation, a 
rapid early fi lling followed by restriction, and left atrial enlargement 
(Figure 2). The main criteria used for diagnosis of endomyocardial 
fi brosis are presented in Table 1.
Computed tomography is seldom used in clinical practice since it 
adds little to the echocardiography. The presence of a linear 
calcifi cation distal to the pericardium, along the inner border of the 
myocardium suggests EMF at conventional and spiral computed 
tomography.(64) Magnetic Resonance Imaging (MRI) confi rms the 
FIGURE 1: Reduction of the ventricular cavity and the characteristic 
image of apical notch, associated with non-cooptation of the 
tricuspid leafl ets, are frequent fi ndings of REMF. There is marked 
spontaneous contrast and right atrial thrombi (T), as well as 
pericardial effusion. In severe cases the left cavities are compressed 
by the right cavities.
T
FIGURE 2:  Thickening of the endocardium of the anterior mitral 
leafl et, the interventricular septum, subvalvar apparatus and apex 
of the LV. There is obliteration (O) of the posterior recess of the 
mitral valve with absence of the posterior mitral leafl et. There is 
reduction of the left ventricular volume and dilatation of the left 
atrium. Left cavities are compressed by the right cavities.
O
existence of thrombus or calcifi cations, allows an exact delineation 
of hypoperfused areas that correspond to fi brosis(65) and provides 
functional information,(65,66) but is not readily available in most 
endemic areas.(67)
Cardiac catheterisation is seldom used due to the imbalance 
between the information obtained and the risk of the pro-
cedure. It is not adequate for diagnosis of localised or mild forms 
of disease where tissue can be obtained from unaffected sites, 
and may be technically challenging in areas of dense endo-
cardial fi brous thickening in advanced disease. The procedure is 
associated with (a) bleeding from venous puncture sites due to 
high venous pressure; (b) diffi culty in entering the right ventricle 
and pulmonary artery due to markedly dilated right atrium, 
tricuspid regurgitation, small right ventricular cavity, and distorted 
and displaced right ventricular outfl ow tract; (c) high risk of 
pulmonary thrombo-embolism from right atrial thrombi; (d) and 
considerable risk of acute hemodynamic deterioration due to 
stimulation of atrial tachyarrhythmia. However, it can be useful in 
differentiating mild forms from early constrictive pericarditis.
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In right EMF pressures in the right atrium, right ventricle, and 
pulmonary artery are equal both in form and amplitude, and 
angiograms show fl attened apex, loss of trabeculated pattern, 
dilated and hypercontractile infundibulum, free tricuspid refl ux, 
large right atrium and dilated cava veins.(68) Left EMF is charact-
erised by very high left ventricular end-diastolic pressure with dip-
plateau pattern, pulmonary hypertension variably damped by 
the presence of the RV disease, and the angiogram shows left 
apical obliteration with varying degree of mitral regurgitation. 
Endomyocardial biopsy is not essential for the diagnosis of EMF 
in endemic areas. It can be misleading when tissue is obtained 
from unaffected sites and is technically diffi cult in areas of dense 
endocardial fi brous thickening. 
Differential diagnosis
In Africa it is important to differentiate left EMF from mitral valve 
disease due to rheumatic heart disease. The large atria associated 
with small ventricles characteristic of bilateral EMF allow easy 
differentiation from dilated cardiomyopathy. Finally, tuberculous 
and constrictive pericarditis must also be considered, as well as 
neoplastic infi ltration by lymphomas, particularly in children and 
young adults.
Management
Although no specifi c therapy for EMF is available, amelioration of 
acute disease, heart failure and arrhythmias, can be achieved with 
corticosteroids, diuretics, vasodilators, digitalis, B-blockers and 
anticoagulants. The overall results of medical therapy have been 
improving lately but patients with advanced disease need large 
doses of drugs and frequent admissions to hospital for invasive 
procedures to alleviate effusions (pericardial, pleural and peri-
toneal) and control arrhythmias. 
Surgery is indicated in patients in NYHA class III and IV since it 
increases survival and quality of life when compared to medical 
therapy.(69) It should be performed before irreversible cardiac 
and hepatic damage occurs.(70) 
 
In Africa due to the lack of human and material resources for 
open-heart surgery in most endemic areas, the surgical experience 
has been growing slowly. A translational research project including 
surgical treatment is underway in Mozambique.(3) The results of 
surgery have been improving with the use of new surgical 
procedures based on better understanding of the pathophysiology 
of EMF and tailored to the structural abnormalities detected.(71)
 
PERIPARTUM CARDIOMYOPATHY                                   
Defi nition
Peripartum cardiomyopathy (PPCM) is a devastating form of 
heart failure in which left ventricular systolic dysfunction and 
symptoms of heart failure occur in a previously healthy women 
during the late stages of pregnancy or within a few months 
postpartum, usually in the last month of pregnancy and the fi rst 
5 months postpartum.(19,72) 
Epidemiology
There are no large population studies on the incidence and 
prognosis of PPCM in Africa. Hospital-based studies report 
an incidence of 1:1 000 deliveries in South Africa(15) and 1:500 
TABLE 1:   Criteria used for diagnosis of established 
endomyocardial fi brosis
 Right ventricular EMF 
Thickened RV endocardium usually in 
septal and apical portions with 
adherent tricuspid valve apparatus
Obliteration of trabecular portion of 
the RV
TV dysfunction (mainly regurgitation)
Endocardial calcifi cation on the right 
ventricle
Pulmonary valve diastolic opening 
and dilated hypercontractile right 
ventricular outfl ow tract
Tall E wave on tricuspid Doppler fl ow
Dilated right atrium
Large pericardial effusion
Spontaneous contrast or intracavitary 
thrombi
Apical notch or shrunken right 
ventricle
 Left ventricular EMF
Thickened LV endocardium usually in 
the apex and posterior wall with 
plastered posterior mitral leafl et
Obliteration of LV apex/posterior 
recess
MV dysfunction (mainly regurgitation) 
Endocardial calcifi cation on the left 
ventricle
M-movement of interventricular 
septum and/or posterior wall




Spontaneous contrast or intra-
cavitary thrombi






















deliveries in Nigeria,(73) showing that the incidence is higher than 
that reported in other parts of the world.(15,19,20,74,75) 
Although the highest incidence of PPCM has been reported 
in women > 30 years of age,(76) it can occur at any age and is 
frequently seen in young women in Africa and after their fi rst 
pregnancy.
Etiology and pathogenesis
The etiology of PPCM remains unknown but viral, autoimmune and 
idiopathic myocarditis are highly suggested.(19) Several hypotheses 
have been put forward namely myocarditis, viral infection, 
autoimmune factors, infl ammatory cytokines, abnormal hemo-
dynamic response to physiological changes in pregnancy, pro-
longed tocolysis and selenium defi ciency.(76,77,78,79,80)  
There are discrepancies in the incidence of myocarditis in 
PPCM that may be due to differences in timing of the myocardial 
biopsy.(81) While an incidence of myocarditis of about 78% has 
been reported in newly diagnosed PPCM patients,(81) failure to 
demonstrate the presence of myocarditis is also common.(82) There 
is also some evidence that infl ammation – possibly related to 
autoimmunity – may play a role in the pathogenesis in early stages 
of the disease process.(83) More recently a study at a single 
tertiary level hospital in South Africa showed raised levels of 
infl ammation markers as evidence for a role of apoptosis in 
PPCM patients.(84)
The major risk factors reported for PPCM are black race, 
advanced maternal age, multiple gestations, twin pregnancy, 
gestational hypertension and long-term tocolysis.(18,19,80)
Although the pathophysiology remains largely unknown, a specifi c 
mechanism has emerged with the recent discovery of an oxidative 
stress-cathepsin D-16-KDA prolactin cascade in experimental 
and human PPCM.(85) 
Clinical presentation and investigations
The clinical presentation of patients with PPCM is similar to that 
of patients with dilated cardiomyopathy. Patients with PPCM 
most commonly present with dyspnea but other frequent 
complaints include cough, orthopnoea, paroxysmal nocturnal 
dyspnea, haemoptysis, and chest discomfort. ECG fi ndings may 
include sinus tachycardia, non-specifi c ST and T wave abnormali-
ties, and voltage abnormalities. The chest radiograph typically shows 
enlargement of the cardiac silhouette with evidence of pulmonary 
venous congestion or interstitial oedema, or both. On chest 
radiography there may be evidence of cardiomegaly, left ventri-
cular hypertrophy, pulmonary oedema, pulmonary venous 
congestion and bilateral pleural effusion. 
Doppler echocardiography is the most widely used procedure for 
diagnosis showing usually dilated ventricles with marked systolic 
dysfunction, commonly associated with atrial enlargement, mitral 
and tricuspid regurgitation, and a small pericardial effusion.(86) 
Elevated pulmonary artery pressure and pulmonary arterial 
hypertension are also seen in the majority of cases.(86) Ventricular 
thrombosis is common (Figure 3) and has been reported in up 
FIGURE 3:  Dilation of the ventricles, severe myocardial 
dysfunction and ventricular thrombi are characteristic features of 
peripartum cardiomyopathy.
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to 53% of patients with peripartum cardiomyopathy.(76,87) Recent 
thrombi are more shaggy and irregular in confi guration, whereas 
organised thrombi are more circumscribed and immobile.(88)
Some evidence exists for the usefulness of MRI for diagnosis, 
pathogenic and prognostic consideration in patients with PPCM.(89) 
Cardiac catheterisation can be used for evaluation of left ventri-
cular function, obtaining endomyocardial biopsies and performing 
coronary angiography, but is not essential to diagnosis in most 
cases.
Diagnosis
The criteria currently used for diagnosis of PPCM are symptoms 
of heart failure or echocardiographic diagnosis of left ventri-
cular dysfunction (left ventricular ejection fraction <0.45; left 
ventricular fractional shortening <30%; left ventricular end-diastolic 
dimension >2.7cm/m2 body surface area), occurring one 
month before or in the 5 months after delivery, in the absence of 
an alternative cause of heart failure and any recognisable heart 
disease before last month of pregnancy.(78,79)
Differential diagnosis
Peripartum cardiomyopathy presenting as congestive heart failure 
affecting African women in late pregnancy or in the early puer-
perium, must be differentiated from dilated cardiomyopathy, 
endomyocardial fi brosis and HIV-related cardiomyopathy, which 
are also very common. Similarly, other secondary forms of cardio-
myopathy must be ruled out, namely pre-eclampsia, infections, 
anemia, thiamine defi ciency and alcoholism.
In women with post-natal pre-cordial pain, in which situation the 
differentiation can present a diagnostic dilemma,(90) symptoms of 
exercise-related chest pain, exertional dyspnea, and orthopnea 
point to a primary cardiac pathology, and the clinical signs of 
pulmonary oedema and gallop rhythm usually exclude a thrombo-
embolic cause.
Complications
The main complications of PPCM are thromboembolism, 
arrhythmias, organ failure, and obstetric and perinatal 
complications.
Systemic and pulmonary thromboembolism, described in a 
considerable number of patients with left ventricular dysfunction, is 
thought to be due to hypercoagulability and risk of thrombosis 
during pregnancy and postpartum period, including activation of 
coagulation factors, increase in plasma fi brinogen, and platelet 
adhesion. The risk of thrombosis is aggravated by the need for 
prolonged rest due to congestive heart failure.
Arrhythmias found in women with PPCM include sinus tachycardia, 
atrial and ventricular tachycardia, atrial and ventricular premature 
beats. Ventricular arrhythmia is thought to be the cause of sudden 
death reported in PPCM.
Organ failure is caused by passive congestion associated with 
hypoperfusion due to cardiac failure and low cardiac output. 
Perinatal complications include premature delivery, small for date 
and low birth weight babies, intrauterine growth retardation and 
fetal deaths(91,92) and higher infant mortality.(77)
Management 
A multidisciplinary approach involving an obstetrician, cardiologist, 
anesthesiologist and perinatologist may be required to provide 
optimal care to PPCM patients.(78,84,87) The current management 
of this condition consists of medical therapy using inotropic 
support, diuretics, beta-blockers, vasodilators (angiotensin-
converting enzyme inhibitors, nitrates or hydralazine) and 
anticoagulants. Although there is currently no consensus as to 
whether patients with depressed left ventricular function and 
sinus rhythm should be anticoagulated to prevent thrombus 
formation, PPCM presents a higher risk and might need aggressive 
and pre-emptive coagulation once the diagnosis is made.(93) The 
role of immunosupression has not been clearly defi ned, but seems 
to have a place in myocarditis-positive PPCM patients.(94) Immuno-
modulation using pentoxifylline has been used due to its capacity 
to reduce production of TNFα, CRP and Fas/Apo-1 (a marker of 
apoptosis), but further studies are needed to clarify its effects.(95,96) 
More recently, the use of bromocryptine (inhibitor of prolactine) 
was successful in preventing left ventricular dysfunction in 
subsequent pregnancies of women known to have had PPCM.(97) 
Effective medical treatment reduces mortality rates and increases 
the number of women who fully recover left ventricular systolic 





















the fetus or breast-feeding infant must be borne in mind. While 
hyponatremia has been reported in infants born from mothers 
taking diuretics prepartum, angiotensin-converting enzyme 
inhibitors are absolutely contraindicated prepartum, when they 
may be associated with adverse fetal renal effects and an increase 
in neonatal mortality.(90) Beta-blockers are generally safe in 
pregnancy.(95)
Surgical management with cardiac transplantation is indicated in 
severe cases with progression of left ventricular dysfunction despite 
medical therapy. Mechanical ventricular assistance can be used as 
a bridge to transplantation.(98)
Outcome 
The course and outcome of this cardiomyopathy are largely 
unpredictable. Maternal mortality, initially reported to reach 85%,(76) 
has now decreased to 9%-50%.(17,84,91,99,100) About half patients 
with PPCM recover,(19,84,99) while 25% evolve to death within 
3 months due to heart failure, arrhythmias or thromboembolism, 
and the remaining patients develop dilated cardiomyopathy 
(Figure 3). The overall prognosis has been improved with 
increase in the percentage of women who recover left ventricular 
function and reduction of mortality, due to advances in the 
therapeutics of heart failure in recent years, mainly the arrival 
of new drugs to treat heart failure, the benefi ts of cardiac 
transplantation and the use of mechanical ventricular assist 
systems.(98) 
 
Recent studies show that Troponin T levels can predict persistent 
left ventricular dysfunction in peripartum cardiomyopathy(101) and 
found that baseline Fas/Apo-1 and higher NHYA at presentation 
were the only predictors of mortality.(96) MRI using late gadolinium 
enhancement may be useful for the evaluation of the extent of 
myocardial damage and to predict the outcome of PPCM.(89) 
Risk of recurrence in future pregnancies
The risk of developing PPCM in subsequent pregnancies remains 
high,(19) although the factors involved in the prognosis are still not 
fully understood and diversity in clinical features of PPCM causes 
diffi culties in making recommendations for future pregnancies. 
The mechanism of recurrent symptomatic heart failure in patients 
with a history of PPCM and recovered left ventricular function has 
been attributed to a signifi cant physiological increase in blood 
volume, stroke volume and heart rate during pregnancy,(102) but 
the fi nding of marked depression of in left ventricular function 
with subsequent pregnancy suggests that worsening of symptoms 
are also due to reactivation of the underlying idiopathic process 
responsible for the development of cardiomyopathy in previous 
pregnancy.(103) While the outcome of subsequent pregnancies is 
better in women who have fully recovered heart function,(84) 
persistence of left ventricular dysfunction after 6 months indicates 
irreversible cardiomyopathy and portends worse prognosis.(18) 
Currently available data suggest that in patients with persistent left 
ventricular dysfunction strong recommendation to avoid additional 
pregnancies is warranted, while preconception counseling in patients 
with recovered left ventricular function is less consensual.(19,92,104) 
 
Research on neglected cardiomyopathies in Africa
Due to their obscure etiology and pathogenesis, the challenges 
posed to their diagnosis and management, and their poor overall 
prognosis, cardiomyopathies have always attracted the interest of 
the scientifi c community. However, while in developed countries 
research and availability of effective management options have 
lead to improvement in prognosis of those that are most preva-
lent, cardiomyopathies peculiar to Africa have been ignored for 
long time. This is demonstrated by the lack of studies on their 
incidence, prevalence, determinants and outcome of these diseases 
in Africa.(2) 
Neglected cardiomyopathies are currently a cause of major 
concern to African individuals, health managers, cardiologists and 
researchers. However, due to lack of human and material resources 
for research in most endemic areas, there is need for the creation 
of networks of local researchers that will be dedicated to investigate 
these diseases. This effort could be supported and coordinated 
by continental health professional organisations, with the involve-
ment of African universities and non-governmental organisations 
dedicated to delivery of health care, professional training and 
cardiovascular research. Academic and sponsoring institutions 
in the developed world should be supportive of projects designed 
and lead by local investigators.(105) 
 
Particularly for EMF and PPCM most publications from Africa are 
several years old, based on small numbers of patients and/or 
using older criteria for diagnosis, which did not include echo-
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cardiography. We are of the opinion that the proposed risk 
factors associated with these cardiomyopathies requires serious 
reevaluation and that actual incidence could be estimated using 
modifi ed diagnostic criteria, particularly in endemic areas. 
Herewith a description of two projects studying these entities in 
African countries: Mozambique and South Africa.
Endomyocardial fi brosis project (Mozambique)
The Heart Institute of Mozambique is a non-governmental 
organisation lead by local cardiologists, devoted to diagnosis, 
treatment and prevention of cardiovascular diseases, as well as 
research into African–specifi c forms of cardiovascular diseases. 
It is a non-profi table institution that is established in Maputo city 
(the capital of Mozambique). Renowned cardiovascular teams 
from France, England, Portugal, Switzerland and Italy contribute 
with open-heart surgery performed in Mozambique periodically, 
while the local team is being trained. The research programme has 
been supported by the Magdi Yacoub Institute (London, UK), 
which has been sponsoring the training programme and the 
establishment of the research laboratories.
Large-scale studies using echocardiographic screening to determine 
the prevalence, incidence and determinants of EMF are being 
performed in a remote rural area with high prevalence of the 
disease in the south of Mozambique (Inharrime), situated 400kms 
from Maputo city, since January 2005. These community-based 
studies have been coupled with clinical and fundamental research, 
with the aim to understand the pathogenesis and mechanisms of 
the disease, and develop new approaches to the management of 
this condition. 
Transthoracic echocardiography was used for the screening of 
1 359 individuals randomly selected in the endemic rural area: 
1 063 individuals at their houses and 296 children from local schools 
(Figure 4). Additionally, a National Clinical Registry has been 
established, including 196 patients referred from all parts of the 
country, which are being followed up. A total of 432 individuals 
with the diagnosis of endomyocardial fi brosis are therefore being 
studied, of which 236 were detected during community studies. 
In reaching out to the population in its environment the initial 
stages of the disease that were not previously described, can now 
be detected.(33) This ongoing research, through follow up of 
cohorts of individuals who are well characterised by echocardio-
graphy, gives a unique opportunity to defi ne the natural history of 
EMF, investigate its determinants and defi ne the mechanisms 
involved in the pathogenesis. On the other hand new therapeutic 
approaches have been evolved and applied with improvement 
of management and prognosis.(71)
The Heart of Soweto Project (South Africa)
The Soweto Cardiovascular Research Unit was set up in January 
2006 to co-ordinate a range of research into cardiovascular 
disease in Soweto, South Africa. It is a collaborative project, bringing 
together internationally renowned academics that will examine 
several questions in relation to the emergence of heart disease in 
Soweto and other African communities in epidemiological transition. 
The Heart of Soweto Study aims to address our poor under-
standing of the characteristics and burden imposed by cardio-
vascular disease in an African setting. It comprises projects with 
particular interest in peripartum and dilated cardiomyopathies, 
which are being undertaken through collaborative projects between 
Universities in South Africa, USA and Germany.(106)
An initial work identifi ed 4 162 cases of cardiovascular disease, 
of which 1 593 newly diagnosed in 2006.(107) Among the 1 593 
newly diagnosed cases, heart failure was the most common primary 
diagnosis (44% of cases) with most cases due to dilated cardio-
FIGURE 4:  Echocardiographic screening in a remote rural area of 
Mozambique during community studies is being used for 
establishment of cohorts that will contribute to better under-






















myopathy (36%) and largely confi ned to black African patients 
(91%).(107) The high incidence of PPCM in this community of 
South Africa has provided a unique opportunity to initiate studies 
of the mechanisms, clinical features and prognostic markers in 
this disease. A randomised clinical trial to explore bromocriptine 
as a new therapy is currently underway.
CONCLUSIONS                                                                
These two projects show that there is awareness about the 
relevance of cardiomyopathies in Africa and that local cardio-
vascular specialists are willing to be the stakeholders for the 
movement aiming to revert the unacceptable situation of neglected 
cardiomyopathies in this continent. The emphasis of the research 
projects has been towards etiology and pathogenesis, with an 
ultimate goal of preventing the occurrence of cardiomyopathies 
and/or changing their natural history.   
Future research should include prospective case-control studies 
to help identify the mechanisms of the disease, and defi ne 
the role of environmental factors (such as parasites, viruses, 
nutritional factors, allergens) as well as that of immunogenetic 
susceptibility. New knowledge gained in several fi elds such as 
endothelial cell biology, infl ammation, hemostasis, regulation of 
collagen synthesis, remodeling and mechanisms of fi brosis, must 
be incorporated into these research projects, aiming at altering 
the natural history and the management of these conditions.
These projects might allow the development of community-based 
programmes of health care in response to local cardiovascular 
problems. Importantly, in the process, the team of internationally 
renowned investigators will build local research capacity to 
develop sustainable programmes of research and high quality 
health services in African countries. Both the international 
collaboration in the medical fi eld and the research outcomes will 
impact the lives of millions of individuals living in similar com-
munities in Africa and other parts of the world. 
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